FDA Accepts Supplemental NDA for Travere's Filspari (Sparsentan)
The FDA has accepted a supplemental NDA for Filspari (Sparsentan) from Travere.
Therapeutic Area
Therapeutic area intelligence for Drug with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.